interpregnancy interval after pregnancy loss miscarriage, time to conception after miscarriage optimal waiting, pregnancy loss how long wait before trying again, Schliep interpregnancy interval pregnancy loss, miscarriage recurrence risk interpregnancy interval, conception timing after early pregnancy loss, fertility after miscarriage waiting period recommendation, Schisterman pregnancy loss interpregnancy interval outcomes, spontaneous abortion subsequent pregnancy timing, miscarriage recovery fertility counseling waiting period
DOI 10.1016/j.fertnstert.2015.07.357 10.1016/j.fertnstert.2015.07.357
Cite this article
Schliep, K., Mitchell, E., Mumford, S., Radin, R., Zarek, S., & Schisterman, E. (2015). Trying to conceive after a pregnancy loss: how long should couples wait?. Fertility and Sterility, 104(3), e115-e116. https://doi.org/10.1016/j.fertnstert.2015.07.357
Schliep K, Mitchell E, Mumford S, Radin R, Zarek S, Schisterman E. Trying to conceive after a pregnancy loss: how long should couples wait?. Fertility and Sterility. 2015;104(3):e115-e116. doi:10.1016/j.fertnstert.2015.07.357
Schliep, K., et al. "Trying to conceive after a pregnancy loss: how long should couples wait?." Fertility and Sterility, vol. 104, no. 3, 2015, pp. e115-e116.
Related articles
PregnancyInterpregnancy IntervalPost-MiscarriagePregnancy Loss Guidelines
Practice Committee of the American Society for Reproductive Medicine and Practice Committee of the Society for Reproductive Endocrinology and Infertility, 2026·Fertility and sterility
Luteal phase deficiency (LPD) is a clinical diagnosis associated with abnormal luteal phase length of ≤10 days. Potential etiologies of LPD include inadequate progesterone duration, inadequate progesterone levels, or endometrial progesterone resistance. Luteal phase deficiency has been described in association with medical conditions, but also in fertile, normally menstruating women. Although progesterone is important for the process of implantation and early embryonic development, LPD has not been proven to be an independent entity causing infertility or recurrent pregnancy loss. Controversy exists regarding the multiple proposed measures for diagnosing LPD, and assuming it can be diagnosed accurately, whether treatment improves outcomes. This document replaces the document of the same name, last published in 2021 (Fertil Steril 2021;115(6):1416-23).
Practice Committee of the American Society for Reproductive Medicine, 2026·Fertility and Sterility
Current strategies for the assessment and treatment of recurrent pregnancy loss are discussed. This replaces the previous document, titled, "Evaluation and treatment a committee opinion," last published in 2012.
This narrative review examines the evidence for medical optimization of inflammatory conditions, vitamin deficiencies, endocrine disorders, immune dysregulation, oligo-ovulation, and luteal phase factors to improve fertility outcomes in women attempting to conceive through natural or timed intercourse. Overall, there is a paucity of data with respect to these categories among patients pursuing timed intercourse, precluding our ability to draw strong recommendations. However, there is strong evidence supporting treatment of endocrine disorders, specifically overt thyroid dysfunction and hyperprolactinemia, as well as oligo-ovulation. Conversely, treatment of subclinical hypothyroidism is not recommended. The current data are insufficient to support empiric use of antiinflammatory medications, corticosteroids, thyroid hormones, or vitamins or supplements to improve chances of pregnancy in a general infertility population.